Soleil Securities downgrades Mindray Medical (NYSE: MR) from Buy to Hold and lowers the price target from $44 to $27. The firm cites a "hazy" outlook for the future.
索雷尔证券集团(Soleil Securities Group)把迈瑞医疗公司评级从买入下调到持有，把目标股价从44美元降低到27美元，表示该公司未来前景尚不明朗。
Soleil Securities downgrades Mindray Medical (NYSE: MR) from Buy to Hold and lowers the price target from $44 to $27. The firm cites a "hazy" outlook for the future.
索雷尔证券集团(Soleil Securities Group)把迈瑞医疗公司评级从买入下调到持有，把目标股价从44美元降低到27美元，表示该公司未来前景尚不明朗。
应用推荐